The race to be first to market with a Covid-19 vaccine is already in advanced stages with several names deep into their candidates’ Phase 3 trials.While several “big pharma” representatives are among the leading pack, the coronavirus has also provided several small cap biotechs a platform on which to gain traction.A latecomer to the race is VBI Vaccines (VBIV). The company certainly won’t make it across the finish line first, but as the pandemic evolves, could have a role to play further down the line.VBI recently secured $42 million in funding from the Canadian government to advance development of its …read more
Source:: Yahoo Finance
